View Post

Optimal Sequencing Remains a Hurdle in Ovarian Cancer Treatment

In Clinical Studies News by Barbara Jacoby

By: Brittany Lovely From: The surge of treatment options for patients with ovarian cancer poses a daunting challenge as answers for optimal sequencing continue to elude clinicians. Bevacizumab (Avastin) continues to hold the most utility in this disease setting, but the addition of PARP inhibitors, and immunotherapy raises the question of how to best deliver efficient regimens to patients. …